A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy | Zendy

Weihua Zhuang | Zendy; Boxuan Ma | Zendy; Gongyan Liu | Zendy; Xiaobing Chen | Zendy; Yunbing Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy

Author(s) -

Weihua Zhuang,

Boxuan Ma,

Gongyan Liu,

Xiaobing Chen,

Yunbing Wang

Publication year - 2017

Publication title -

regenerative biomaterials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.166

H-Index - 25

ISSN - 2056-3426

DOI - 10.1093/rb/rbx012

Subject(s) - micelle , cisplatin , phosphorylcholine , chemistry , copolymer , drug , cytotoxicity , in vitro , combinatorial chemistry , biophysics , polymer , pharmacology , organic chemistry , biochemistry , chemotherapy , aqueous solution , medicine , surgery , biology

cis-dichlorodiammineplatinum(II) (CDDP)-loaded polymeric micelles for cancer therapy have been developed to reduce the serious side effects of cisplatin CDDP. Herein, polymeric micelles incorporated with cisplatin are prepared based on the complexation between CDDP and hydrophilic poly ( L -glutamic acid)-b-poly (2-methacryloyloxyethyl phosphorylcholine) (PLG-b-PMPC) diblock copolymers. These CDDP-loaded micelles possess an average size of 91 nm with narrow distribution, providing remarkable stability in media containing proteins. The release of CDDP from the micelles is faster at pH 5.0 and pH 6.0 than that at pH 7.4 and in a sustained manner without initial burst release. In addition, there is almost no difference in cellular uptake between these CDDP-loaded micelles and free CDDP. Moreover, in vitro cytotoxicity test shows they possess high efficacy to kill 4T1 cells as compared with free drug. Thus, PLG-b-PMPC copolymer might be a promising carrier for CDDP incorporating in cancer therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research